Revenue

9 Months Ended

Sep. 30, 2021

Revenue

Revenue

9. Revenue

The Group’s revenue is primarily derived from the sale of ZEJULA, Optune and QINLOCK in China and Hong Kong. The table below presents the Group’s net product sales for the three and nine months ended September 30, 2021 and 2020.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
	$			$			$			$
Product revenue - gross		47,555			17,152			135,490			37,567
Less: Rebate and sales return		(4,452	)		(2,501	)		(35,349	)		(3,703	)
Product revenue - net		43,103			14,651			100,141			33,864

Sales rebates are offered to distributors in China and the amounts are recorded as a reduction of revenue. Estimated rebates are determined based on contracted rates, sales volumes and level of distributor inventories.

The sales rebates included nil and $22,009 compensation to distributors for those products previously sold at the price prior to the National Reimbursement Drug List (“NRDL”) implementation, due to the first-time inclusion of ZEJULA in the NRDL, for the three and nine months ended September 30, 2021. There was no such compensation for the three and nine months ended September 30, 2020.

The following table disaggregates net revenue by product for the three and nine months ended September 30, 2021 and 2020:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
	$		$		$		$
ZEJULA		28,162		8,503		64,134		22,294
Optune		10,653		5,950		27,318		11,372
QINLOCK		4,288		198		8,689		198
Product revenue - net		43,103		14,651		100,141		33,864